Cancers, Vol. 16, Pages 1417: Safety of the Breast Cancer Adjuvant Radiotherapy in Ataxia & ndash;Telangiectasia Mutated Variant Carriers

Cancers, Vol. 16, Pages 1417: Safety of the Breast Cancer Adjuvant Radiotherapy in Ataxia–Telangiectasia Mutated Variant Carriers Cancers doi: 10.3390/cancers16071417 Authors: Rayan Bensenane Arnaud Beddok Fabienne Lesueur Alain Fourquet Mathilde Warcoin Marine Le Mentec Eve Cavaciuti Dorothée Le Gal Séverine Eon-Marchais Nadine Andrieu Dominique Stoppa-Lyonnet Youlia Kirova The Ataxia–Telangiectasia Mutated (ATM) gene is implicated in DNA double-strand break repair. Controversies in clinical radiosensitivity remain known for monoallelic carriers of the ATM pathogenic variant (PV). An evaluation of the single-nucleotide polymorphism (SNP) rs1801516 (G-A) showed different results regarding late subcutaneous fibrosis after breast radiation therapy (RT). The main objective of this study was to evaluate acute and late toxicities in carriers of a rare ATM PV or predicted PV and in carriers of minor allele A of rs1801516 facing breast RT. Fifty women with localized breast cancer treated with adjuvant RT between 2000 and 2014 at Institut Curie were selected. Acute and late toxicities in carriers of a rare PV or predicted PV (n= 9), in noncarriers (n = 41) and in carriers of SNP rs1801516 (G-A) (n = 8), were examined. The median age at diagnosis was 53 years old and 82% of patients had an invasive ductal carcinoma and 84% were at clinical stage I–IIB. With a median follow-up of 13 years, no significant difference b...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research